Lupin Pushes Philippines Expansion With Minority Stake Deal Timeline

Lupin Limited has announced that its acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. will now be completed in July 2026, subject to closing conditions. The transaction, initially expected by May, is being executed through Nanomi B.V., Lupin’s Netherlands-based wholly owned subsidiary.  

The update underscores Lupin’s strategic focus on strengthening its footprint in Southeast Asia. Multicare Pharmaceuticals, a subsidiary of Nanomi, plays a key role in Lupin’s regional growth strategy, and full consolidation of ownership is expected to enhance operational efficiency and market presence.  

Strategic update

Regional impact

Key highlights  

• Minority stake acquisition in Multicare Pharmaceuticals Philippines  
• Transaction completion now expected in July 2026  
• Deal executed via Nanomi B.V., Lupin’s Netherlands subsidiary  
• Strengthens Lupin’s Southeast Asia footprint  
• Enhances operational control and market expansion strategy  
  
  

Sources: Company filing, Lupin SE Intimation, May 29, 2026